Are antibody heavy and light chains really randomly paired, or are there rules? We sat down with @josefng1.bsky.social, who introduced ImmunoMatch, a recently published framework for predicting heavy/light chain compatibility. This could be a new way to rank candidates before functional validation.

Our next High Affinity talks is tomorrow! 🎙️ We're welcoming Joseph Ng from UCL, creator of ImmunoMatch, a machine learning framework trained on paired human B cell sequences to predict chain compatibility and trace its role in B cell development and maturation. Register here: bit.ly/4aZrM9o

Antibody discovery is moving fast. But too many teams are still slowed down by fragmented tools, custom scripts, and bioinformatics bottlenecks. That’s why we're hosting a virtual masterclass on how leading pharma and biotech teams are accelerating lead selection. Sign up here: bit.ly/4ajVyVS

Choosing an Antibody Discovery Platform: A 2026 Landscape Review We compared the current leaders based on five key criteria: - End-to-end workflow coverage - Scientist-first usability - Functionality and visualizations - Computational throughput - Data control + flexibility bit.ly/3LSJFhP

The most valuable AI in antibody discovery isn’t “generative.” It’s a filter Labs don’t need 10,000 novel sequences we can’t make. We need AI to flag those that won't survive The real ROI? Kill bad clones in silico Saving weeks of failed experiments > hallucinating a “perfect” binder that crashes

The analysis gap is the biggest bottleneck in antibody discovery. Too often, teams must choose between fragmented scripts or opaque black-box tools. Our app note shows how Platforma enables deep repertoire sequencing, functional clustering, and diversity-first selection to cut redundancy and risk.

Excited to host our first webinar of the year! We're partnering with @miltenyibiotec.bsky.social to feature their new next-generation bulk RNA library preparation solution for TCR α/β profiling with advanced analysis and visualization in Platforma. Register here: bit.ly/4jFH3Qv Feb 5th @ 5 PM CET

A decade ago, immune repertoire sequencing was niche. Today, it’s population-scale. From 3.5M TCR/BCR samples on MiXCR, key trends emerge: • Bulk amplicon remains the workhorse • Single-cell is growing fastest (>50% YoY) • Academia customizes; industry standardizes Full article: bit.ly/4suV1ZG

What a year for our global research community 🌍 In 2025, together we: • Processed 1.5 PB of data (+50% YoY) • Welcomed 2,400 new users across 375 institutions • Were cited in 741 publications • Shipped 30 new biological blocks On to an even bigger 2026 🚀

What if we’ve been studying TILs wrong? A new low-intervention study found: — High-TIL areas had both CD4+ and CD8+ T cells — Low-TIL areas skewed to CD4+ T cells with fewer cytotoxic markers — CD4+ T cells had less diverse TCRs MiXCR identified TILs with the highest therapeutic potential.

Antibody discovery becomes far more powerful when functional assay data and NGS are brought together. In Platforma’s antibody space, overlaying immune assay targets with clonotypes makes enriched, functionally validated clones pop instantly, letting teams spot high-value hits faster.

Coupled with other filters for sequence liability and enrichment scores, this decision funnel guarantees a panel of leads that are both enriched and biologically diverse. Couldn't make it to our webinar? Watch the recording on-demand: www.youtube.com/watch?v=hhsL...

Last week during our antibody discovery webinar, we gave a live demo of our lead selection block. Unlike the common “Top N” approach, which can bias selection toward a single dominant family, we use a Diversity-First algorithm to pick the top representative from each family to ensure diversity.

Last chance to register for our antibody discovery webinar tomorrow at 11 AM EST/ 5 PM CET! Learn how to: • Uncover emergent clones & immune responses • Track enrichment and liabilities • Predict structure & affinity from sequence • Find top leads without coding Sign up here: t.co/3Ye6fj1EAA

Wrapping up our last Platforma Pioneers workshop at @bostonchildrens.bsky.social! Joining forces with over 40 members of the Harvard network, our team helped spark collaboration and share knowledge, empowering biologists to run their own downstream analyses themselves. Thank you for hosting us!

Want to learn more about how top teams combine sequence, functional, and structural analysis to prioritize true therapeutic candidates? Join our webinar next week. bit.ly/4oY9s69

What everyone in antibody discovery should know: 1. How to combine NGS with functional assay data to reveal truly high-potential clones 2. Not all lead candidates are therapeutic candidates 3. Prioritize developability from the start. Spot sequence liabilities early to derisk your pipeline.

MiXCR powered BCR extraction in this study, and with Platforma you can now go further—model structure, predict binding affinity, and rank top antibody leads by developability. Learn more here: platforma.bio/antibody-dis... #antibody #antibodydiscovery #antibodyengineering

🧬 New deep learning model profiles antigen–antibody interactions at scale! Cmai predicts antigen–BCR binding from standard RNA-seq with >0.90 AUROC—unlocking biomarker discovery, treatment response prediction, and even forecasting immune-related toxicities up to 120 days before onset.

Platforma Pioneers Tour — UCSD & @lji.org 40 researchers, one clear takeaway: Platforma bridges the gap. Biologists can analyze data without waiting Core facilities empower users beyond count matrices Bioinformaticians can focus on innovation Platforma doesn't replace expertise, it unlocks it.

Want to accelerate your antibody discovery workflow? Join our webinar to learn how to prioritize lead candidates faster. You’ll discover how to track enrichment and liabilities, monitor clone dynamics over time, and predict developability to minimize risk Register here: bit.ly/4p8157W

This week, we kicked off our Platforma Pioneers academic tour at UCLA! Our hands-on workshop on how to accelerate no-code NGS data analysis with Platforma was a blast. A big thank you to everyone who joined us—we loved seeing your curiosity and creativity in action! 🚗 Next stops - USC and UCSD!

RNA-seq to monitor minimal residual disease (MRD) in multiple myeloma? A recent Nature study found that RNA-seq achieved higher sensitivity and stronger prognostic value than DNA-seq for MRD. We're proud that MiXCR was the key tool in this study. Read more here: x.com/MiLaboratori...

We just wrapped up two impactful days at the Cell Symposium in Sitges, Spain with Cellecta! Was great to be face-to-face with researchers: live demos of Platforma, learning more about what others are working on, and sharing what our teams have been building. Thanks to everyone who stopped by!

Proud to share a new study advancing non-invasive immune monitoring in cancer. Researchers found tumor-derived TCR clonotypes enriched in cfDNA and persisting >50 weeks in circulating T cells. Proud that MiXCR powered large-scale TCR sequencing across tumor, blood, and cfDNA. #cfDNA #TCRseq #TCR

Big news: we’ve launched an interactive demo on the Platforma website! Choose your own scientific adventure: 🔹 Antibody Discovery 🔹 Differential Gene Expression 🔹 Single Cell Multiomics 🔹 TCR/BCR Repertoire Analysis 👉 Dive into the demo here: shorturl.at/7tkD4 #NGS #Multiomics #TCR #BCR

🧬 Join our team: We’re hiring a Scientific Sales Development Representative in Bilbao! Who you are: Degree in Biology/Bioinformatics (or similar), strong English, 0–2 years’ experience lnkd.in/dxMXRT84

🔬 Empowering the next generation of scientists! Today, our team hosted a hands-on Platforma workshop at the University of Navarra, where researchers explored Platforma's powerful functionalities hands on with real datasets. Thanks to everyone who joined! #bioinformatics #NGS

🔬 Transform your B-cell research with Platforma - no coding required: ✔️ Annotate & build clonotypes with quality controls ✔️ Run clonality analyses across studies & patient groups ✔️ Cluster B cells, perform differential analysis, & explore UMAP bit.ly/42QDhNb Download today: platforma.bio

Although we couldn’t make it to #ASHG2025, our partner Illumina presented a fantastic study on accurate full-length V(D)J clonotype detection using high-quality long reads on the MiSeq™ i100. We’re especially proud that MiXCR was used to enable precise immune repertoire profiling.

A major leap forward in treatment for Addison’s Disease! In a new publication from bioRxiv, researchers pinpointed IFN-γ–producing self-reactive CD4+ T cells as the main drivers of autoimmune adrenalitis in a mouse model. We're proud that MiXCR enabled analysis of TCR clonotypes from scRNAseq.

Gene expression analysis with bulk RNA-seq data traditionally involves many steps (preprocessing, differential expression, pathway enrichment) + bioinformatics expertise Platforma changes that. Watch how we perform gene expression analysis in just a few clicks. www.youtube.com/watch?v=K7aq...

New Case Study featuring MiXCR + Qiagen: University of Antwerp pioneers “celluloepidemiology", revealing infections missed by antibodies and unique signatures linked to long COVID. Find out how they scaled TCR profiling for population-level insights and cut prep time by 25%. bit.ly/498lvsu

You might know us as the creators of MiXCR, and now we've launched Platforma for more powerful downstream functionalities without the coding bottleneck. #NGS #singlecell #VDJ #bioinformatics

Congratulations to Nobel Laureate Shimon Sakaguchi for his groundbreaking work on regulatory T cells! 🧬 We're proud to see our technology, MiXCR, supporting his lab’s research. In a recent study, MiXCR helped the team decode TCR repertoires. Proud to support science that changes the world. 🌍

Biologists design brilliant experiments...then lose momentum waiting for results. That’s why we built Platforma, to put the power of analysis directly into biologists’ hands. 🎥 Watch the demo to see how Platforma takes you from raw data to validated T-cell insights, without any coding.

October is Breast Cancer Awareness Month, a timely moment to spotlight new advances in how we understand and treat this disease. 🎗️ A recently study explores dynamic systemic immune responses in early-stage HR+ patients receiving chemotherapy + immunotherapy. Read more here: shorturl.at/jOQkO

Fast insights from single-cell data without coding With Platforma, you can: 🔹 Explore UMAPs & Leiden clusters 🔹 Integrate transcriptomics + VDJ metrics 🔹 Visualize clonotypes & sequence similarities 🔹 Overlay gene expression across clusters 🎥 youtu.be/FrsS3YDauhg #singlecell #VDJ #NGS

A new study from @ox.ac.uk shows why HR+ patients with lymph node metastasis fare worse: - Weakened Defense: Tumor-reactive CD8 T cells are scarce, impairing cancer surveillance. - Early-Stage Window: Early HR+ patients have a robust, diverse circulating CD8 TCR More details: shorturl.at/0HP2l

We’re thrilled to team up with @yefis-immunology.bsky.social for our next webinar! 📅 October 7th, 16:00 CET Platforma was built to make cutting-edge bioinformatics accessible to every scientist, so anyone can turn raw NGS into meaningful insights without coding. 🔗 Register here: shorturl.at/AQtCD

Last week we hosted a webinar with Kiel University and shared valuable insights on T-cell responses against EBV (Epstein–Barr Virus) and its implications for advancing research and therapeutic development. Weren't able to attend? 🎥 Watch the recording here: www.youtube.com/watch?v=l2Q8...

💡Why repertoire clonality matters and how to analyze it Done right, repertoire analysis transforms sequencing data into actionable insights for immune monitoring and therapy evaluation. bit.ly/4gBZlRp

Location, location, location. Developing a multimodal framework, new research from @bcmhouston.bsky.social reveals that a T cell's location within a tumor is a major factor influencing its function. We're proud that MiXCR enabled comprehensive TCR repertoire profiling in this study.

Prioritizing antibody candidates shouldn’t require coding bioinformatics expertise. With Platforma, biologists in academia or pharma can analyze NGS data independently, explore motifs, predict liabilities, and select the best antibody leads with confidence. #antibody #bcr #bioinformatics

🚨 Last chance to register! We’re going live tomorrow to explore the link between Epstein-Barr Virus (EBV) and Primary Sclerosing Cholangitis (PSC) with insights from large-scale immune profiling. 📅 Wednesday, Sep 17 @ 3:00 PM GMT+2 💻 Live demo included Register here: shorturl.at/E4tpj

🌍 Exciting news! We’ve launched the Platforma Ambassador Program—a chance for researchers to host workshops, lead user groups, and join a global network of innovators in bioinformatics. Gain training, travel grants & career growth. Apply by Sept 21 👉 shorturl.at/KN2Ju

For the first time, CLL's immune dysfunction has been mapped at single-cell resolution. A new @nature.com study reveals galectin-9 is a key driver of T-cell exhaustion and linked to worse outcomes. Using MiXCR, scientists reconstructed TCR repertoires to uncover these dynamics #CLL #TCell #TCR

🦠 Could Epstein–Barr virus (EBV) be a hidden driver of chronic liver disease? A new Nature Medicine study shows EBV may play a major role in primary sclerosing cholangitis (PSC). 🧵 Key findings ⬇️

9 patients. 40 months. 0 recurrences. 💉 A new Nature study shows the power of personalized cancer vaccines. With the help of MiXCR, researchers designed vaccines targeting each patient’s tumor profile, leading to strong T cell responses. A big step for immunotherapy in hard-to-treat cancers.

✨ Feeling the energy at IUIS! The excitement is contagious, and we loved sharing a live demo of Platforma with so many of you today. 🚀 If you missed it, no worries — we’ll be back tomorrow at 11 AM at the Cellecta booth. Come by to see the future of immune profiling.